Dynavax Technologies Stock Forecast, Price & News

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

Is Dynavax Technologies a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies or view top-rated stocks.

What stocks does MarketBeat like better than Dynavax Technologies?

Wall Street analysts have given Dynavax Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dynavax Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Dynavax Technologies.

How can I listen to Dynavax Technologies' earnings call?

Dynavax Technologies will be holding an earnings conference call on Thursday, November 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) released its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.06. The biopharmaceutical company had revenue of $52.77 million for the quarter, compared to analyst estimates of $44.04 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 7.33% and a negative net margin of 3.37%.
View Dynavax Technologies' earnings history.

How has Dynavax Technologies' stock been impacted by Coronavirus?

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DVAX shares have increased by 524.4% and is now trading at $19.17.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for DVAX?

3 Wall Street analysts have issued 1 year price targets for Dynavax Technologies' stock. Their forecasts range from $19.00 to $23.00. On average, they expect Dynavax Technologies' share price to reach $21.00 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts' price targets for Dynavax Technologies or view top-rated stocks among Wall Street analysts.

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the following people:

• Ryan Spencer, Chief Executive Officer & Director
• David F. Novack, President & Chief Operating Officer (LinkedIn Profile)
• Kelly MacDonald, Chief Financial Officer & Senior Vice President
• Robert Janssen, Chief Medical Officer & SVP-Clinical Development (LinkedIn Profile)
• John L. Slebir, Senior Vice President & General Counsel

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dynavax Technologies' key competitors?

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of DVAX's competitors.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (2.90%), Assenagon Asset Management S.A. (0.86%), First Hawaiian Bank (0.04%), Hanseatic Management Services Inc. (0.03%), Strs Ohio (0.02%) and Wedbush Securities Inc. (0.02%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David F Novack, David F Novack, Justin Burgess and Robert Janssen.
View institutional ownership trends for Dynavax Technologies.

Which institutional investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include Andrew A F Hack, David F Novack, Justin Burgess, and Robert Janssen.
View insider buying and selling activity for Dynavax Technologies or view top insider-selling stocks.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Assenagon Asset Management S.A., Hanseatic Management Services Inc., Strs Ohio, First Hawaiian Bank, CAPROCK Group Inc., Kestra Advisory Services LLC, and NEXT Financial Group Inc.
View insider buying and selling activity for Dynavax Technologies or or view top insider-buying stocks.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $19.17.

How much money does Dynavax Technologies make?

Dynavax Technologies has a market capitalization of $2.20 billion and generates $46.55 million in revenue each year. The biopharmaceutical company earns $-75.24 million in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Dynavax Technologies have?

Dynavax Technologies employs 245 workers across the globe.

When was Dynavax Technologies founded?

Dynavax Technologies was founded in 1996.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is www.dynavax.com.

Where are Dynavax Technologies' headquarters?

Dynavax Technologies is headquartered at 2100 Powell Street Suite 900, Emeryville CA, 94608.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at (510) 848-5100 or via email at [email protected].